HER2 discordance between primary and metastatic breast cancer: Assessing the clinical impact

2013 ◽  
Vol 39 (8) ◽  
pp. 947-957 ◽  
Author(s):  
Natalie H. Turner ◽  
Angelo Di Leo
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Clinical Impact

scholarly journals Clinical Impact of FDG-PET/CT Compared with CE-CT in Response Monitoring of Metastatic Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (16) ◽  
pp. 4080
Author(s):  
Mohammad Naghavi-Behzad ◽  
Hjalte Rasmus Oltmann ◽  
Tural Asgharzadeh Alamdari ◽  
Jakob Lykke Bülow ◽  
Lasse Ljungstrøm ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Computed Tomography ◽  
Metastatic Breast Cancer ◽  
Stable Disease ◽  
Fdg Pet ◽  
Metastatic Breast ◽  
Clinical Impact ◽  
Response Monitoring ◽  
Pet Ct ◽  
Fdg Pet Ct

We compared response categories and impacts on treatment decisions for metastatic breast cancer (MBC) patients that are response-monitored with contrast-enhanced computed-tomography (CE-CT) or fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT). A comparative diagnostic study was performed on MBC patients undergoing response monitoring by CE-CT (n = 34) or FDG-PET/CT (n = 31) at the Odense University Hospital (Denmark). The responses were assessed visually and allocated into categories of complete response (CR/CMR), partial response (PR/PMR), stable disease (SD/SMD), and progressive disease (PD/PMD). Response categories, clinical impact, and positive predictive values (PPV) were compared for follow-up scans. A total of 286 CE-CT and 189 FDG-PET/CT response monitoring scans were performed. Response categories were distributed into CR (3.8%), PR (8.4%), SD (70.6%), PD (15%), and others (2.1%) by CE-CT and into CMR (22.2%), PMR (23.8%), SMD (31.2%), PMD (18.5%), and others (4.4%) by FDG-PET/CT, revealing a significant difference between the groups (P < 0.001). PD and PMD caused changes of treatment in 79.1% and 60%, respectively (P = 0.083). PPV for CE-CT and FDG-PET/CT was 0.85 (95% CI: 0.72–0.97) and 0.70 (95% CI: 0.53–0.87), respectively (P = 0.17). FDG-PET/CT indicated regression of disease more frequently than CE-CT, while CE-CT indicated stable disease more often. FDG-PET/CT seems to be more sensitive than CE-CT for monitoring response in metastatic breast cancer.

P117. Clinical impact of PET-CT on patient management in metastatic breast cancer

2015 ◽  
Vol 41 (6) ◽  
pp. S59-S60
Author(s):  
Mark Phillips ◽  
Kieran Horgan ◽  
Andrew Scarsbrook ◽  
Bhavani Rengabashyam
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Patient Management ◽  
Metastatic Breast ◽  
Clinical Impact ◽  
Pet Ct
Sign in / Sign up

Export Citation Format

Share Document